{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T17:57:28Z","timestamp":1777485448780,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T00:00:00Z","timestamp":1487116800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s12094-017-1618-1","type":"journal-article","created":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T08:14:28Z","timestamp":1487146468000},"page":"874-883","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2V617F mutations and laboratory findings: a meta-analysis"],"prefix":"10.1007","volume":"19","author":[{"given":"N.","family":"Saki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Shirzad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Rahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0952-5861","authenticated-orcid":false,"given":"A.","family":"Saki Malehi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,15]]},"reference":[{"key":"1618_CR1","unstructured":"Johansson P editor, Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Seminars in thrombosis and hemostasis; 2006: Copyright\u00a9 2006 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA."},{"issue":"5","key":"1618_CR2","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937\u201351.","journal-title":"Blood"},{"issue":"10","key":"1618_CR3","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1182\/blood.V96.10.3310","volume":"96","author":"AA Axelrad","year":"2000","unstructured":"Axelrad AA, Eskinazi D, Correa PN, Amato D. Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia. Blood. 2000;96(10):3310\u201321.","journal-title":"Blood"},{"issue":"2","key":"1618_CR4","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood.V100.2.714","volume":"100","author":"L Teofili","year":"2002","unstructured":"Teofili L, Pierconti F, Di Febo A, Maggiano N, Vianelli N, Ascani S, et al. The expression pattern of c-mpl in megakaryocytes correlates with thrombotic risk in essential thrombocythemia. Blood. 2002;100(2):714\u20137.","journal-title":"Blood"},{"issue":"14","key":"1618_CR5","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","volume":"123","author":"P Lundberg","year":"2014","unstructured":"Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014;123(14):2220\u20138.","journal-title":"Blood"},{"issue":"4","key":"1618_CR6","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/leu.2011.314","volume":"26","author":"H Reikvam","year":"2012","unstructured":"Reikvam H, Tiu RV. Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera. Leukemia. 2012;26(4):563\u201371.","journal-title":"Leukemia"},{"issue":"25","key":"1618_CR7","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379\u201390.","journal-title":"N Engl J Med"},{"issue":"10","key":"1618_CR8","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1182\/blood-2007-11-125328","volume":"111","author":"J-J Kiladjian","year":"2008","unstructured":"Kiladjian J-J, Cervantes F, Leebeek FW, Marzac C, Cassinat B, Chevret S, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood. 2008;111(10):4922\u20139.","journal-title":"Blood"},{"issue":"9","key":"1618_CR9","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1038\/leu.2014.138","volume":"28","author":"R Fu","year":"2014","unstructured":"Fu R, Xuan M, Zhou Y, Sun T, Bai J, Cao Z, et al. Analysis of calreticulin mutations in Chinese patients with essential thrombocythemia: clinical implications in diagnosis, prognosis and treatment. Leukemia. 2014;28(9):1912\u20134.","journal-title":"Leukemia."},{"issue":"7414","key":"1618_CR10","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ Br Med J. 2003;327(7414):557.","journal-title":"BMJ Br Med J"},{"issue":"7109","key":"1618_CR11","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"issue":"3","key":"1618_CR12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388.","journal-title":"Control Clin Trials"},{"issue":"4","key":"1618_CR13","first-page":"719","volume":"22","author":"N Mantel","year":"1959","unstructured":"Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Nat Cancer Inst. 1959;22(4):719\u201348.","journal-title":"J Nat CAncer Inst"},{"issue":"25","key":"1618_CR14","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391\u2013405.","journal-title":"N Engl J Med."},{"issue":"10","key":"1618_CR15","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","volume":"123","author":"G Rotunno","year":"2014","unstructured":"Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2014;123(10):1552\u20135.","journal-title":"Blood."},{"issue":"10","key":"1618_CR16","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","volume":"123","author":"E Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123(10):1544\u201351.","journal-title":"Blood."},{"key":"1618_CR17","doi-asserted-by":"crossref","unstructured":"Tefferi A, Wassie EA, Guglielmelli P, Gangat N, Belachew AA, Lasho TL, et al. Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol. 2014.","DOI":"10.1002\/ajh.23743"},{"issue":"7","key":"1618_CR18","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3324\/haematol.2014.107482","volume":"99","author":"H Andrikovics","year":"2014","unstructured":"Andrikovics H, Krahling T, Balassa K, Halm G, Bors A, Koszarska M, et al. Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations. Haematol. 2014;99(7):1184\u201390.","journal-title":"Haematol."},{"issue":"12","key":"1618_CR19","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1007\/s00277-014-2151-8","volume":"93","author":"C-C Chen","year":"2014","unstructured":"Chen C-C, Gau J-P, Chou H-J, You J-Y, Huang C-E, Chen Y-Y, et al. Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia. Annals Hematol. 2014;93(12):2029\u201336.","journal-title":"Annals Hematol."},{"key":"1618_CR20","doi-asserted-by":"crossref","unstructured":"Shirane S, Araki M, Morishita S, Edahiro Y, Takei H, Yoo Y, et al. JAK2, CALR, and MPL mutation spectrum in Japanese myeloproliferative neoplasms patients. Haematologica. 2014.115113.","DOI":"10.3324\/haematol.2014.115113"},{"key":"1618_CR21","doi-asserted-by":"crossref","unstructured":"Tefferi A, Wassie E, Lasho T, Finke C, Belachew A, Ketterling R, et al. Calreticulin mutations and long-term survival in essential thrombocythemia. Leukemia. 2014.","DOI":"10.1038\/leu.2014.148"},{"issue":"3","key":"1618_CR22","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s12253-014-9885-4","volume":"21","author":"E Posfai","year":"2015","unstructured":"Posfai E, Marton I, Kiraly PA, Kotosz B, Kiss-Laszlo Z, Szell M, et al. JAK2 V617F, MPL, and CALR mutations in essential thrombocythaemia and major thrombotic complications: a single-institute retrospective analysis. Pathol Oncol Res: POR. 2015;21(3):751\u20138.","journal-title":"Pathol Oncol Res : POR."},{"issue":"5","key":"1618_CR23","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1309\/AJCPUAAC16LIWZMM","volume":"143","author":"SY Kim","year":"2015","unstructured":"Kim SY, Im K, Park SN, Kwon J, Kim JA, Lee DS. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable. Am J Clin pathol. 2015;143(5):635\u201344.","journal-title":"Am J Clin pathol."},{"issue":"1","key":"1618_CR24","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/bjh.13076","volume":"168","author":"AP Trifa","year":"2015","unstructured":"Trifa AP, Popp RA, Cucuianu A, Banescu C, Tevet M, Martin B, et al. CALR versus JAK2 mutated essential thrombocythaemia\u2013a report on 141 patients. British J Haematol. 2015;168(1):151\u20133.","journal-title":"British J Haematol."},{"issue":"1","key":"1618_CR25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.leukres.2008.06.006","volume":"33","author":"IJ Dahabreh","year":"2009","unstructured":"Dahabreh IJ, Zoi K, Giannouli S, Zoi C, Loukopoulos D, Voulgarelis M. Is JAK2 V617F mutation more than a diagnostic index?: a meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res. 2009;33(1):67\u201373.","journal-title":"Leuk Res"},{"issue":"11","key":"1618_CR26","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1161\/01.ATV.17.11.2359","volume":"17","author":"E Dai","year":"1997","unstructured":"Dai E, Stewart M, Ritchie B, Mesaeli N, Raha S, Kolodziejczyk D, et al. Calreticulin, a potential vascular regulatory protein, reduces intimal hyperplasia after arterial injury. Arterioscler Thromb Vasc Biol. 1997;17(11):2359\u201368.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"14","key":"1618_CR27","doi-asserted-by":"crossref","first-page":"8179","DOI":"10.1074\/jbc.270.14.8179","volume":"270","author":"K Kuwabara","year":"1995","unstructured":"Kuwabara K, Pinsky DJ, Schmidt AM, Benedict B, Brett B, Ogawa S, et al. Calreticulin, an antithrombotic agent which binds to vitamin K-dependent coagulation factors, stimulates endothelial nitric oxide production, and limits thrombosis in canine coronary arteries. J Biol Chem. 1995;270(14):8179\u201387.","journal-title":"J Biol Chem"},{"issue":"2","key":"1618_CR28","first-page":"169","volume":"91","author":"E Arellano-Rodrigo","year":"2006","unstructured":"Arellano-Rodrigo E, Alvarez-Larr\u00e1n A, Reverter JC, Villamor N, Colomer D, Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica. 2006;91(2):169\u201375.","journal-title":"Haematologica"},{"issue":"5","key":"1618_CR29","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.exphem.2007.01.053","volume":"35","author":"A Falanga","year":"2007","unstructured":"Falanga A, Marchetti M, Vignoli A, Balducci D, Russo L, Guerini V, et al. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematol. 2007;35(5):702\u201311.","journal-title":"Exp Hematol"},{"issue":"13","key":"1618_CR30","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood.V96.13.4261","volume":"96","author":"A Falanga","year":"2000","unstructured":"Falanga A, Marchetti M, Evangelista V, Vignoli A, Licini M, Balicco M, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood. 2000;96(13):4261\u20136.","journal-title":"Blood"},{"issue":"2","key":"1618_CR31","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/00062752-200303000-00009","volume":"10","author":"TM McIntyre","year":"2003","unstructured":"McIntyre TM, Prescott SM, Weyrich AS, Zimmerman GA. Cell\u2013cell interactions: leukocyte\u2013endothelial interactions. Curr Opin Hematol. 2003;10(2):150\u20138.","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"1618_CR32","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMe058093","volume":"353","author":"T Barbui","year":"2005","unstructured":"Barbui T, Finazzi G. When and how to treat essential thrombocythemia. N Engl J Med. 2005;353(1):85\u20136.","journal-title":"N Engl J Med"},{"issue":"12","key":"1618_CR33","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1111\/j.1538-7836.2006.02194.x","volume":"4","author":"N Maugeri","year":"2006","unstructured":"Maugeri N, Giordano G, Petrilli M, Fraticelli V, De Gaetano G, Cerletti C, et al. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug? J Thromb Haemost. 2006;4(12):2593\u20138.","journal-title":"J Thromb Haemost"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-017-1618-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-017-1618-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-017-1618-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T12:05:16Z","timestamp":1601640316000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-017-1618-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,15]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["1618"],"URL":"https:\/\/doi.org\/10.1007\/s12094-017-1618-1","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,15]]}}}